Intera Oncology to acquire Oncology and Neuromodulation Drug Delivery products from Johnson & Johnson

3rd

 Colorectal cancer is the third most commonly diagnosed cancer for both men and women in the United States.

Stop
Recurrence

 For patients who develop metastases in the liver, treating and stopping the recurrence of those tumors is the key to long term survival.

100%

 Intera Oncology is dedicated to substantially improving survival and standard of care for colorectal cancer and cholangiocarcinoma patients.